Merck & Co. (MRK) Announces that US FDA Approves ENFLONSIA™ For Preventing RSV Lower Respiratory Tract Disease

Merck & Co. (MRK) announced FDA approval for ENFLONSIA™ (clesrovimab-cfor), a long-acting monoclonal antibody for preventing RSV lower respiratory tract disease in neonates and infants, with availability targeted before the upcoming RSV season. This approval is a significant pipeline development, offering a new revenue stream for Merck, which is crucial as investors focus on the company's ability to replace sales from its blockbuster Keytruda post-2028 patent expiry and navigate recent challenges like weak Gardasil demand in China, despite strong Q4 earnings and a robust clinical pipeline.

Analysis

Merck & Co. has secured a strategic victory with the FDA approval of ENFLONSIA, a long-acting monoclonal antibody for preventing RSV in infants. This approval positions Merck to tap into the seasonal respiratory infection market, with plans for availability before the next RSV season, representing a tangible step in diversifying its product portfolio. However, this positive pipeline development is set against a challenging backdrop highlighted by investment manager Artisan Partners. The core issue for investors is the impending 2028 patent expiration of the blockbuster oncology drug Keytruda, which accounted for a significant 50% of Q4 sales. This patent cliff is compounded by near-term headwinds, including weak demand for the Gardasil vaccine in China and a planned pause in shipments until mid-2025 to manage inventory. Despite these pressures, which have weighed on sentiment, Artisan Partners notes that Merck's valuation appears low at just 10 times earnings. This suggests the market is currently giving little credit to the company's extensive pipeline of over 60 programs in clinical development, its strong balance sheet, and its robust free cash flow, which together provide significant optionality for future acquisitions, partnerships, and capital returns.

Key Decisions for Investors

• Investors should closely monitor the commercial launch and initial sales trajectory of ENFLONSIA, as its performance will serve as a key early indicator of Merck's ability to diversify revenue ahead of the Keytruda patent cliff.
• The primary long-term catalyst is progress within the late-stage pipeline; positive clinical trial data for potential blockbusters is essential to de-risking the 2028 patent expiration and could trigger a significant re-rating of the stock.
• Given the valuation at 10x earnings, the stock may appeal to value-oriented investors, but this must be weighed against substantial execution risk in the pipeline and near-term volatility from the Gardasil inventory issues.